Tyrphostin AG 1296

Research use only, not for human use.

Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.

6,7-Dimethoxy-3-phenylquinoxaline is an ATP-competitive inhibitor of receptor kinase.

Cell Viability Assay Cell Line:PLX4032-resistant cell lines (A375R and SK-MEL-5R)Concentration:0.625, 1.25, 5, 20 μM Incubation Time:72 h Result:Reduced the viability of both PLX4032-sensitive and PLX4032-resistant cell lines.Apoptosis Analysis Cell Line:A375R cells Concentration:2.5, 5, 10, 20 μM Incubation Time:48 h Result:Induced dramatic apoptosis in A375R cells.Western Blot Analysis Cell Line:A375R cells Concentration:5, 20 μM Incubation Time:2 h Result:Inhibited phosphorylation of both PDGFR-α and PDGFR-β.

Animal Model:Nud/nud mice are injected with A375R cellsDosage:40, 80 mg/kg Administration:I.p. daily for two weeks Result:Led to an intermediate level of tumor growth suppression at dose of 40 mg/kg, and significant inhibition of A375R tumor growth at dose of 80 mg/kg.Well tolerated by healthy mice without significant signs of overt toxicity or weight loss.

6,7-Dimethoxy-3-phenylquinoxaline

Angiogenesis

EGFR

PDGFR

Cardiovascular Disease|Inflammation/Immunology

——

146535-11-7

266.29

C16H14N2O2

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (125.16 mM)

COc1cc2nc(cnc2cc1OC)c3ccccc3

6,7-Dimethoxy-3-phenylquinoxaline

(-20℃)

With Ice Pack

≥ 2 years